GlassScriptPhysician profile
Ahmad Mansury
NPI 1992960827
$2,652.00
in general payments reported to CMS, 2019-2025
8 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $65.10 · 2021: $43.81 · 2022: $244 · 2023: $1,683 · 2024: $32.69 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,290 · Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,290.00 |
| Food and Beverage | $642.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,627.99 | 2019-2025 | Iaccess Precision Blade, Idosetr |
| Alcon Vision LLC | $452.50 | 2019-2023 | Clareon |
| New World Medical,INC. | $241.42 | 2019-2025 | Clearpath, Ahmed Glaucoma Valve, Via360 |
| Johnson & Johnson Surgical Vision, INC. | $94.20 | 2020-2022 | |
| Horizon Therapeutics Plc | $75.32 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $68.86 | 2019 | |
| Amgen INC. | $67.34 | 2024-2025 | Tepezza |
| Rxsight INC | $24.37 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Mansury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.